PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

NARecruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

January 19, 2024

Primary Completion Date

June 14, 2027

Study Completion Date

September 14, 2027

Conditions
Multiple MyelomaComplication
Interventions
BEHAVIORAL

Interpretation of the results from the detection visit

"\- An interpretation of the results of the detection tests concerning~* the 7 complications of interest assessed at T1, T2, T3 and T4 ;~* the 13 secondary complications assessed at T1, T3 and T4. This interpretation will be based on decision trees (1 tree/complication) to guide investigators in their decision-making and to standardise orientations;"

BEHAVIORAL

Explaining detection results and referrals to the patient

"Explanation of results and directions to the patient using plain language;The aims of this call are as follows:~* Clearly explain the results of the detection visit and the action to be taken for each referral;~* Evaluate the help to be given to the patient. This help will consist of making bookings with a healthcare professional in the PASCA network;~* Reassure patients about their results, but also make them aware of the importance of taking action to improve or prevent the onset of complications."

BEHAVIORAL

Early medical care through the network

Early, proactive medical care through a network of dedicated healthcare professionals.

BEHAVIORAL

Transmission of results from each detection visit to the referring onco-haematologists - Control Group

For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective): all the data from each detection visit will be sent to the referring onco-haematologists, so that they can initiate their own management.

Trial Locations (1)

69373

RECRUITING

Centre Léon Bérard, Lyon

All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

lead

Centre Leon Berard

OTHER